Gilead Sciences (GILD) PT Lowered to $82 at BofA Securities

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. AZN
8. CART
9. LLY
10. TSLA

Go back to Gilead Sciences (GILD) PT Lowered to $82 at BofA Securities

Gilead Sciences (GILD), Galapagos NV (GLPG) Report Filgotinib Demonstrates Durable Efficacy & Consistent Safety Profile at 52-Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis

June 4, 2020 6:09 AM EDT

Gilead Sciences, Inc. (NASDQ: GILD) and Galapagos NV (NASDAQ: GLPG) today announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis (RA). The data demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations. The new data are among 15 abstracts on filgotinib in RA that will be presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology... More